Bayer AG sold a minority stake in its contraceptives business to Apollo Global Management for €3 billion ($3.4 billion). The transaction represents a $3.4 billion outflow that Bayer will deploy to strengthen its balance sheet and reduce leverage. Apollo, a private‑equity firm, will acquire a share in Bayer’s contraceptive portfolio, which includes key brands such as Yuzpe and Ortho‑Pharma.

The deal signals Bayer’s strategic shift away from lower‑margin consumer products toward higher‑return pharmaceutical segments. By monetising a minority interest, Bayer unlocks capital without surrendering control, positioning the company to fund research, acquisitions, or debt repayment. Apollo gains exposure to a mature, global contraceptive market with steady cash flows.

For investors, the transaction reduces Bayer’s debt load, potentially lowering credit risk and improving credit ratings. Private‑equity investors gain a foothold in a stable, regulated market, while Bayer can redirect capital to growth initiatives. The deal underscores a broader trend of pharmaceutical firms monetising niche assets to optimise capital structures and focus on core therapeutic areas.